BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 34778045)

  • 1. Targeted Therapeutic Strategies for Triple-Negative Breast Cancer.
    Li Y; Zhan Z; Yin X; Fu S; Deng X
    Front Oncol; 2021; 11():731535. PubMed ID: 34778045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
    Gupta GK; Collier AL; Lee D; Hoefer RA; Zheleva V; Siewertsz van Reesema LL; Tang-Tan AM; Guye ML; Chang DZ; Winston JS; Samli B; Jansen RJ; Petricoin EF; Goetz MP; Bear HD; Tang AH
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32846967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Therapies in Triple-Negative Breast Cancer.
    Marmé F; Schneeweiss A
    Breast Care (Basel); 2015 Jul; 10(3):159-66. PubMed ID: 26557820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in targeted strategies for triple-negative breast cancer.
    Zhu S; Wu Y; Song B; Yi M; Yan Y; Mei Q; Wu K
    J Hematol Oncol; 2023 Aug; 16(1):100. PubMed ID: 37641116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies.
    Khosravi-Shahi P; Cabezón-Gutiérrez L; Custodio-Cabello S
    Asia Pac J Clin Oncol; 2018 Feb; 14(1):32-39. PubMed ID: 28815913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer.
    Tong L; Yu X; Wang S; Chen L; Wu Y
    Breast Cancer (Dove Med Press); 2023; 15():647-658. PubMed ID: 37644916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple-Negative Breast Cancer: The Progress of Targeted Therapies and Future Tendencies.
    Damaskos C; Garmpi A; Nikolettos K; Vavourakis M; Diamantis E; Patsouras A; Farmaki P; Nonni A; Dimitroulis D; Mantas D; Antoniou EA; Nikolettos N; Kontzoglou K; Garmpis N
    Anticancer Res; 2019 Oct; 39(10):5285-5296. PubMed ID: 31570423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target-Oriented Classification of Triple-negative Breast Cancer.
    Mizumoto S; Inubushi S; Miki M; Nakamura H; Baba M; Yamashita Y; Yamamoto M; Inoue S; Tanino H; Kunihisa T
    Anticancer Res; 2023 Nov; 43(11):5067-5072. PubMed ID: 37909966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.
    Park Y; Moriyama A; Kitahara T; Yoshida Y; Urita T; Kato R
    Anticancer Agents Med Chem; 2012 Jul; 12(6):672-7. PubMed ID: 22263793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer.
    Tazzite A; Jouhadi H; Benider A; Nadifi S
    Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. State of art of advanced triple negative breast cancer.
    Khosravi-Shahi P; Cabezón-Gutiérrez L; Aparicio Salcedo MI
    Breast J; 2019 Sep; 25(5):967-970. PubMed ID: 31155832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted approaches to triple-negative breast cancer: current practice and future directions.
    Brunello A; Borgato L; Basso U; Lumachi F; Zagonel V
    Curr Med Chem; 2013; 20(5):605-12. PubMed ID: 23278396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecularly targeted therapies for metastatic triple-negative breast cancer.
    Bayraktar S; Glück S
    Breast Cancer Res Treat; 2013 Feb; 138(1):21-35. PubMed ID: 23358903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into the Emerging Therapeutic Targets of Triple-negative Breast Cancer.
    Varshini MS; Krishnamurthy PT; Reddy RA; Wadhwani A; Chandrashekar VM
    Curr Cancer Drug Targets; 2024 Feb; ():. PubMed ID: 38385495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast Cancer.
    Zhang Z; Zhang R; Li D
    Biologics; 2023; 17():113-128. PubMed ID: 37767463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer.
    Mir MA; Qayoom H; Mehraj U; Nisar S; Bhat B; Wani NA
    Curr Cancer Drug Targets; 2020; 20(8):586-602. PubMed ID: 32418525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple-negative breast cancer: A run-through of features, classification and current therapies.
    Manjunath M; Choudhary B
    Oncol Lett; 2021 Jul; 22(1):512. PubMed ID: 33986872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging targeted therapeutic strategies for the treatment of triple-negative breast cancer.
    Kumari L; Mishra L; Patel P; Sharma N; Gupta GD; Kurmi BD
    J Drug Target; 2023 Dec; 31(9):889-907. PubMed ID: 37539789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast Cancer: Current Molecular Therapeutic Targets and New Players.
    Nagini S
    Anticancer Agents Med Chem; 2017; 17(2):152-163. PubMed ID: 27137076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.